BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16195422)

  • 1. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
    Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemokinin-1 stimulates prostaglandin E₂ production in human colon through activation of cyclooxygenase-2 and inhibition of 15-hydroxyprostaglandin dehydrogenase.
    Dai L; Perera DS; King DW; Southwell BR; Burcher E; Liu L
    J Pharmacol Exp Ther; 2012 Jan; 340(1):27-36. PubMed ID: 21957267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
    Ding Y; Tong M; Liu S; Moscow JA; Tai HH
    Carcinogenesis; 2005 Jan; 26(1):65-72. PubMed ID: 15358636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
    Tong M; Ding Y; Tai HH
    Carcinogenesis; 2006 Nov; 27(11):2170-9. PubMed ID: 16632868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.
    Dai L; King DW; Perera DS; Lubowski DZ; Burcher E; Liu L
    Dig Dis Sci; 2015 May; 60(5):1236-46. PubMed ID: 25666316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
    Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
    Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I; Hasan F; Khan I
    Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of 15-hydroxyprostaglandin dehydrogenase messenger RNA concentration, protein expression, and enzymatic activity during human ureteral obstruction.
    Jerde TJ; Mellon WS; Fischer SM; Liebert M; Bjorling DE; Nakada SY
    J Pharmacol Exp Ther; 2004 Apr; 309(1):398-403. PubMed ID: 14718596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease.
    Horowitz S; Binion DG; Nelson VM; Kanaa Y; Javadi P; Lazarova Z; Andrekopoulos C; Kalyanaraman B; Otterson MF; Rafiee P
    Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1323-36. PubMed ID: 17218473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase.
    Akazawa A; Sakaida I; Higaki S; Kubo Y; Uchida K; Okita K
    J Gastroenterol; 2002; 37(5):345-53. PubMed ID: 12051533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine.
    Klebl FH; Olsen JE; Jain S; Doe WF
    J Pathol; 2001 Dec; 195(5):609-15. PubMed ID: 11745698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use.
    Cui G; Olsen T; Christiansen I; Vonen B; Florholmen J; Goll R
    Scand J Clin Lab Invest; 2006; 66(3):249-59. PubMed ID: 16714253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
    Li M; Xie J; Cheng L; Chang B; Wang Y; Lan X; Zhang D; Yin Y; Cheng N
    Cancer Invest; 2008 Nov; 26(9):905-12. PubMed ID: 19034772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes.
    Miyaki A; Yang P; Tai HH; Subbaramaiah K; Dannenberg AJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G559-66. PubMed ID: 19608733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids and tumor necrosis factor-alpha synergize to induce absorption by the epithelial sodium channel in the colon.
    Bergann T; Zeissig S; Fromm A; Richter JF; Fromm M; Schulzke JD
    Gastroenterology; 2009 Mar; 136(3):933-42. PubMed ID: 19185581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity.
    Lejeune M; Leung P; Beck PL; Chadee K
    Am J Physiol Gastrointest Liver Physiol; 2010 Nov; 299(5):G1097-105. PubMed ID: 20813914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease.
    Renner M; Bergmann G; Krebs I; End C; Lyer S; Hilberg F; Helmke B; Gassler N; Autschbach F; Bikker F; Strobel-Freidekind O; Gronert-Sum S; Benner A; Blaich S; Wittig R; Hudler M; Ligtenberg AJ; Madsen J; Holmskov U; Annese V; Latiano A; Schirmacher P; Amerongen AV; D'Amato M; Kioschis P; Hafner M; Poustka A; Mollenhauer J
    Gastroenterology; 2007 Nov; 133(5):1499-509. PubMed ID: 17983803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease.
    Kruidenier L; Kuiper I; van Duijn W; Marklund SL; van Hogezand RA; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):7-16. PubMed ID: 12950012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
    Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
    Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.